Characterization of Non-Monotonic Relationships between Tumor Mutational Burden and Clinical Outcomes

被引:0
|
作者
Anaya, Jordan [1 ]
Kung, Julia [2 ]
Baras, Alexander S. [1 ,3 ,4 ]
机构
[1] Johns Hopkins Univ, Dept Pathol, Sch Med, CRB II 152,1550 Orleans St, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Biomed Informat & Data Sci, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
来源
CANCER RESEARCH COMMUNICATIONS | 2024年 / 4卷 / 07期
关键词
CTLA-4; BLOCKADE; LANDSCAPE; MODELS;
D O I
10.1158/2767-9764.CRC-24-0061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Potential clinical biomarkers are often assessed with Cox regressions or their ability to differentiate two groups of patients based on a single cutoff. However, both of these approaches assume a monotonic relationship between the potential biomarker and survival. Tumor mutational burden (TMB) is currently being studied as a predictive biomarker for immunotherapy, and a single cutoff is often used to divide patients. In this study, we introduce a two-cutoff approach that allows splitting of patients when a non-monotonic relationship is present and explore the use of neural networks to model more complex relationships of TMB to outcome data. Using real-world data, we find that while in most cases the true relationship between TMB and survival appears monotonic, that is not always the case and researchers should be made aware of this possibility.Significance: When a non-monotonic relationship to survival is present it is not possible to divide patients by a single value of a predictor. Neural networks allow for complex transformations and can be used to correctly split patients when a non-monotonic relationship is present.
引用
收藏
页码:1667 / 1676
页数:10
相关论文
共 50 条
  • [1] Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population
    Gautam, Santosh
    Kachroo, Sumesh
    DeClue, Richard W.
    Fisher, Maxine D.
    Basu, Anirban
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (10) : 857 - 868
  • [2] Approach to evaluating tumor mutational burden in routine clinical practice
    Truesdell, John
    Miller, Vincent A.
    Fabrizio, David
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 678 - 681
  • [3] Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
    Chae, Young Kwang
    Davis, Andrew A.
    Agte, Sarita
    Pan, Alan
    Simon, Nicholas I.
    Iams, Wade T.
    Cruz, Marcelo R.
    Tamragouri, Keerthi
    Rhee, Kyunghoon
    Mohindra, Nisha
    Villaflor, Victoria
    Park, Wungki
    Lopes, Gilberto
    Giles, Francis J.
    ONCOLOGIST, 2019, 24 (06): : 820 - 828
  • [4] The association between tumor mutational burden and prognosis is dependent on treatment context
    Valero, Cristina
    Lee, Mark
    Hoen, Douglas
    Wang, Jingming
    Nadeem, Zaineb
    Patel, Neal
    Postow, Michael A.
    Shoushtari, Alexander N.
    Plitas, George
    Balachandran, Vinod P.
    Smith, J. Joshua
    Crago, Aimee M.
    Roche, Kara C. Long
    Kelly, Daniel W.
    Samstein, Robert M.
    Rana, Satshil
    Ganly, Ian
    Wong, Richard J.
    Hakimi, A. Ari
    Berger, Michael F.
    Zehir, Ahmet
    Solit, David B.
    Ladanyi, Marc
    Riaz, Nadeem
    Chan, Timothy A.
    Seshan, Venkatraman E.
    Morris, Luc G. T.
    NATURE GENETICS, 2021, 53 (01) : 11 - 15
  • [5] Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
    Stenzinger, Albrecht
    Allen, Jeffrey D.
    Maas, Joerg
    Stewart, Mark D.
    Merino, Diana M.
    Wempe, Madison M.
    Dietel, Manfred
    GENES CHROMOSOMES & CANCER, 2019, 58 (08): : 578 - 588
  • [6] Characterization of pancreatic cancer with ultra-low tumor mutational burden
    Imamura, Taisuke
    Ashida, Ryo
    Ohshima, Keiichi
    Uesaka, Katsuhiko
    Sugiura, Teiichi
    Ohgi, Katsuhisa
    Yamada, Mihoko
    Otsuka, Shimpei
    Hatakeyama, Keiichi
    Nagashima, Takeshi
    Sugino, Takashi
    Urakami, Kenichi
    Akiyama, Yasuto
    Yamaguchi, Ken
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations
    Smolle, Elisabeth
    Leithner, Katharina
    Olschewski, Horst
    THORACIC CANCER, 2020, 11 (02) : 205 - 215
  • [8] Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Hendriks, Lizza E.
    Rouleau, Etienne
    Besse, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 647 - 660
  • [9] Tumor mutational burden is associated with poor outcomes in diffuse glioma
    Wang, Lihong
    Ge, Jia
    Lan, Yang
    Shi, Yu
    Luo, Ying
    Tan, Yuhuan
    Liang, Mei
    Deng, Song
    Zhang, Xia
    Wang, Wenying
    Tan, Yaoyao
    Xu, Yuanyuan
    Luo, Tao
    BMC CANCER, 2020, 20 (01)
  • [10] Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
    Garassino, Marina C.
    Gadgeel, Shirish
    Novello, Silvia
    Halmos, Balazs
    Felip, Enriqueta
    Speranza, Giovanna
    Hui, Rina
    Garon, Edward B.
    Horinouchi, Hidehito
    Sugawara, Shunichi
    Rodriguez-Abreu, Delvys
    Reck, Martin
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Piperdi, Bilal
    Pietanza, M. Catherine
    Paz-Ares, Luis
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (01):